Sun Pharmaceutical Industries Ltd: History, Latest Updates, Milestones, Subsidiaries & Share Price

INTRODUCTION

Sun Pharmaceutical Industries Ltd. (Sun Pharma) stands as the fourth largest specialty generic pharmaceutical company worldwide, boasting global revenues amounting to US$ 5.4 billion. Supported by 43 manufacturing facilities, we offer high-quality, affordable medicines trusted by healthcare professionals and patients across more than 100 countries.

Sun Pharma caters to diverse healthcare needs across six continents, including Asia, North America, Europe, Africa, South America, and Australia. An impressive 68% of the company’s total turnover originates from its extensive export operations. Operating more than 40 manufacturing facilities globally underscores Sun Pharma's commitment to ensuring a consistent and reliable supply of medications to numerous individuals worldwide.

Sun Pharmaceutical Industries Ltd. MOVES IN 2024:

Sun Pharmaceutical Industries Limited released its financial report for the quarter ending December 31st, 2023. Here are the key highlights from the consolidated financials for Q3FY24:

Gross sales amounted to Rs. 121,569 million, showing a growth of 9.5%,influencing sun pharma share price.
Sales from India formulations reached Rs. 37,785 million, marking an increase of 11.4%.
US formulation sales totaled US$ 477 million, reflecting a growth of 13.2%. Sun Pharma share price experienced stability amid these positive results.
Global specialty sales stood at US$ 296 million, including a US$ 20 million milestone received in Q3, showing a growth of 24.2% excluding milestones and impacting sun pharma share price.
Research and Development (R&D) investments amounted to Rs. 8,245 million, compared to Rs. 6,702 million in Q3FY23.
The distinctive EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) amounted to Rs. 34,768 million (including other operating revenues), marking a growth of 15.8%. The EBITDA margin for Q3 was 28.1%, compared to 26.7% in Q3FY23 impacting sun pharma share price tremendously.
The unique adjusted net profit (excluding exceptional items) for Q3FY24 was Rs.25,936 million, marking an increase of 19.7%. Reported net profit for Q3FY24 was Rs. 25,238 million compared to Rs. 21,660 million during Q3FY23,affecting sun pharma share price.

Evolution of Sun Pharmaceutical Industries Ltd.: From Past to Present:

1983: Sun Pharmaceutical Industries Ltd. was established with a primary focus on psychiatry products. Starting with just five products and a small marketing team, the company set its roots in Vadodara, India, by establishing its first manufacturing facility for tablets and capsules.
1988: The company expanded its product portfolio by launching its first cardiology products, Mantra and Ang. This expansion allowed Sun Pharma to diversify its product range and make a meaningful impact in another crucial area by establishing a footprint in the cardiology segment.
1992: Sun Pharma made its first foray into the international market.
1994: Sun Pharma made its debut on the public stock exchange, marking a significant milestone in its journey.
1997: Sun Pharma ventured into international acquisitions by acquiring Caraco Pharmaceutical Laboratories in the USA.
2000: The acquisition of Propharma in India contributed to expanding Sun Pharma's product portfolio.
2004: Sun Pharma established its first joint venture manufacturing unit in Dhaka and acquired Picopain and niche brands from MJ Pharma in the USA.
2005: Sun Pharma further expanded its manufacturing capabilities by acquiring a manufacturing unit in Bryan, Ohio, USA, and acquired ICN's operations in Hungary from Valeant Pharma, enhancing its global footprint.
2010: Sun Pharma gained control of a significant stake in Taro Pharmaceuticals, headquartered in the USA, leading to a significant increase in the company's business in the United States.
2012: Sun Pharma acquired DUSA Pharmaceuticals and the generic business of URL Pharma in the USA.
2014: Sun Pharma made a significant acquisition by purchasing Ranbaxy for US$4 billion, becoming the world's fifth-largest specialty generic pharmaceutical company. Additionally, it acquired Pharmalucence in the USA.
2015: Sun Pharma acquired GSK's OTC business in Australia.
2019: Sun Pharma launched the specialty product Cequa in the United States for dry eye treatment.
2021: Sun Pharma entered the nutrition bar market in India by introducing Revital NXT to the market.
2022: The company expanded its global reach by acquiring the active pharmaceutical ingredient portfolio from Teva Pharma in Romania.

Name	Sun Pharmaceutical Industries Ltd.
Founded year	1983
Founding chairman	Dilip Shanghvi
Headquarters	Mumbai, India.
Sector	Pharmaceuticals
Current chairman	Dilip Shanghvi (MD)
Major subsidiaries	Ranbaxy Laboratories
revenue	Rs. 44,520 crore (US$5.6 billion) (FY23)
Geographical presence	Worldwide
Nse code	SUNPHARMA
Bse code	524715

Timeline of Sun Pharmaceutical Industries Ltd.:

Year	Title	Description
2024	Sustainability	Sun Pharma included in S&P global sustainability index for its commitment to sustainable practices
2023	Acquisition	Sun Pharma acquired Concert Pharmaceuticals in USA to expand its presence
2022	Portfolio	Sun Pharma acquired Uractiv portfolio from Fiterman Pharma in Romania to strengthen its portfolio
2021	Launches	Sun Pharma launched ILUMYA™ (tildrakizumab injection) in Canada for psoriasis treatment
		Sun Pharma launched WINLEVI® cream 1% in the U.S., offering a novel dermatological solution for Acne Vulgaris treatment
		Sun Pharma entered the nutrition bar segment in India with Revital NXT
2020	Anniversary	Sun Pharma completed 25 years since debut on the Indian Stock Exchanges
2020	Anniversary	Sun Pharma launched ILUMYA™ for plaque psoriasis treatment in Japan
2019	Expansion	Sun Pharma acquired Pola Pharma in Japan to enhance its presence
2019	Expansion	Sun Pharma launched Cequa in the United States for dry eyes treatment
2017	Odomzo Launch	Sun Pharma launched Odomzo in the USA for skin cancer treatment
2016	Acquisitions	Sun Pharma acquired 14 brands from Novartis in Japan and Ocular Technologies, Sarl to expand its portfolio
		Sun Pharma acquired Biosintez to enhance its presence in the Russian market
		Sun Pharma launched BromSite™, its first branded ophthalmic product, in the USA
2015	Business Expansion	Sun Pharma acquired GSK’s Opiates business in Australia and InSite Vision Inc. in the USA
2014	Ranbaxy Acquisition	Sun Pharma's acquisition of Ranbaxy for US$ 4 billion propelled it to become the world’s 5th largest generic pharmaceutical company.
2014	Licensing Agreement	Sun Pharma acquired Pharmalucence in the USA to expand its presence
2012	Pharmaceutical Acquisitions	Sun Pharma acquired Dusa Pharmaceuticals and the generic business of URL Pharmaceuticals in USA
2010	Taro Acquisition	Sun Pharma acquired controlling stake in Taro Pharmaceuticals, doubling its US business
2008	Chemicals Purchase	Sun Pharma acquired Chattem Chemicals Inc, USA to expand its footprint
2004	Formulation Unit	Sun Pharma set up a new formulation unit in Jammu, India to expand its capabilities
2001	Production Commencement	Sun Pharma commenced production at its new formulations unit in Dadra, India
2000	Company Acquisition	Sun Pharma acquired Pradeep Drug Company in India to enhance its operations
1997	Equity Stakes	Sun Pharma purchased equity stakes in TDPL and MJ Pharma to strengthen its position
	International Expansion	Sun Pharma acquired Caraco Pharmaceutical Laboratories, USA for international expansion
	Research Facility	Sun Pharma established a new research facility in Mumbai, India
1996	Global Expansion	Sun Pharma expanded its sales network across 24 countries and acquired API plant from Knoll Pharma in India
1995	Manufacturing Plant	Sun Pharma began production at API manufacturing plant in Panoli, Gujarat, India
1994	Public Offering	Sun Pharma launched its Initial Public Offering (IPO)
1991	Research Center	Sun Pharma established its first research center for product and process development
1988	Cardiology Products	Sun Pharma launched Monotrate and Angize, its first cardiology products
1983	Establishment	Sun Pharma was founded with five psychiatry products and a two-person marketing team in Vapi, Gujarat, India.

Inside Sun Pharmaceutical Industries Ltd.: Exploring Subsidiary Ventures

Sun Pharmaceutical Industries Ltd.

Corporate actions: On February 9, 2024, an interim dividend of 8.50 was declared for equity shares, with the ex-date and record date being the same.

Main News: Sun Pharma is set to acquire a 16.33% stake in the U.S. firm Surgimatix for $3.05 million.

Main News: On January 31, 2024, Sun Pharmaceutical Industries Ltd. announced a 16.52% increase in its third-quarter consolidated net profit, reaching Rs. 2,524 crore compared to Rs. 2,166 crore In the corresponding period from the previous year. Gross sales also experienced a 9.5% growth, reaching Rs. 12,157 crore. Specifically, India formulation sales rose by 11.4% to Rs. 3,778.5 crore, and U.S. formulation sales increased by 13.2% to $477 million.

TARO Pharmaceuticals

Main News: Taro has announced a merger with Sun Pharma in a deal worth Rs. 2,892 crore. Once the merger is finalized, anticipated to occur in the first half of 2024, Taro will transition into a privately held entity, and its shares will cease trading on the NYSE.

Sun Pharmaceutical Industries Ltd. share price NSE Today:

COMPANY NAME	SECTOR	SHARE PRICE LINK
sun pharma share price nse today	Pharmaceutical and Drugs	Sun Pharmaceutical Industries Ltd share price

Achievements and milestones:

Year	Achievement
2023	Achieved Great Place to Work certification.
2022	Achieved Great Place to Work certification.
2021	the company was honored with the Golden Peacock Award for Corporate Social Responsibility..
	Won the Dun & Bradstreet India Corporate Award in the Pharmaceuticals category.
	Received the DIANA award for 'Best New Product Introduction/Promotion'.
	The company received the accolade of Best Innovative Company of the Year at the Indo-American Corporate Excellence Awards.
2020	Listed among the Forbes World’s Best Employers.
	Volini was listed in the Nielsen BASES Top Breakthrough Innovation Winners India 2020.
	Ranked No. 1 in the pharma sector and No. 16 overall in BW Businessworld's list of India’s Most Respected Companies.

CONCLUSION

Sun Pharma remains steadfast in its commitment to improving global health. From its inception, Sun Pharmaceutical has prioritized providing high-quality medication at affordable prices, ensuring accessibility for all. With a rich history marked by growth and innovation, the company continuously solidifies its global presence, positioning itself as a leader in the pharmaceutical industry. Its diverse product portfolio and dedicated team underscore its unwavering dedication to promoting health and well-being. Additionally, the company keeps a close eye on market dynamics, ensuring transparency and efficiency in its operations, which in turn positively impact Sun Pharma share price.

Enrich Money offers investors the opportunity to invest in Sun Pharma stocks with ease, providing a free demat and trading account for seamless trading experience and financial growth.

Frequently Asked Questions:

Where can I find the sun pharma share price today?

To check the sun pharma share price today, please visit the sun pharma share price today on Enrich Money page

What is the current market cap of sun pharma?

The Market Capitalization of the sun pharmaceutical industries share price today is Rs. 3.71 trillion.

What has been the highest sun pharmaceutical industries ltd share price in the last 52 weeks?

52 Week's highest of sun pharmaceutical industries ltd share price is Rs1,072.15, while 52 week's low is Rs 789.90

What is the sun pharma share price value?

sun pharma share price/face value is Rs. 1

What factors influence Sun Pharma share price?

Several factors can influence Sun Pharma share price, including company performance, market sentiment, industry trends, regulatory changes, and macroeconomic factors.

How can I analyze Sun Pharma share price trends?

You can analyze Sun Pharma share price trends using technical analysis tools of ORCA APP.

Disclaimer: This blog is dedicated exclusively for educational purposes. Please note that the securities and investments mentioned here are provided for informative purposes only and should not be construed as recommendations. Kindly ensure thorough research prior to making any investment decisions. Participation in the securities market carries inherent risks, and it's important to carefully review all associated documents before committing to investments. Please be aware that the attainment of investment objectives is not guaranteed. It's important to note that the past performance of securities and instruments does not reliably predict future performance.